Process and methods
1 Decision problem, description of the technology and clinical care pathway
Please choose the most appropriate option(s) from those provided in the submission template about whether the submission covers:
all or only part of the technology's marketing authorisation for this indication
all or only part of the population for whom the comparator has been recommended by NICE.
Present the decision problem in the table in section 1.1 of the template, making reference to the final NICE scope.
Provide details of the technology being appraised using the table in section 1.1 of the template.
1.3.1 Present the clinical pathway of care that shows the context and the proposed placement of the technology within the pathway. This information should be summarised in a diagram if possible. If a relevant NICE guideline has been published, the response to this point should be consistent with the guideline and any differences should be explained. If the management of the condition has changed since the NICE technology appraisal(s) of the comparator(s) specified in the final scope, highlight and explain the differences.
1.4.1 NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. For further information about equality issues see NICE's equality scheme.
1.4.2 Provide an assessment of whether the use of this technology is likely to raise any equality issues. Please document any potential issues that:
could exclude from full consideration any people protected by the equality legislation who fall within the patient population for whom the technology is or will be licensed
could lead to recommendations that have a different impact on people protected by the equality legislation compared with the wider population, for example, by making it more difficult in practice for a specific group to access the technology
could lead to recommendations that have any adverse impact on people with a particular disability or disabilities.
1.4.3 Please provide any evidence that would enable the committee to identify and consider the impact of equality issues. State how the analysis has addressed these issues.